TARS (TARS) DEF 14A Filing Completed April 28

Tarsus Pharmaceuticals (TARS) submitted its DEF 14A filing on April 28. This form typically outlines important information for shareholders, including governance issues and executive compensation. Such filings are essential for transparency and can influence investor sentiment and company valuations. As of the latest data, TARS aims to provide detailed disclosures to its shareholders, which can positively affect market confidence.